Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS-mUC: Immunotherapy-Based Combinations in Cisplatin-Ineligible Metastatic Urothelial Carcinoma After Platinum Failure
2017-004634-28Phase 2Active
- Sponsor
- Roche
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in transitional cell carcinoma (TCC) (6 arms), sponsored by Roche. Primary endpoint: Objective response rate. Started Dec 2018; status: active.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2017-004634-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004634-28.